Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.50 |
| ▸ | QDPR | P09417 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 4/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.46 |
| ▸ | DRD1 | P21728 | 2/20 | 0.46 |
| ▸ | DRD5 | P21918 | 2/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.46 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.45 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 2/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17067813 | 0.89 | ACMSD (0.57) | ACMSDNOTUMDHODH | |
| SCHEMBL30760594 | 0.86 | QDPR (0.49) | QDPRHTR2CSIGMAR1SLC18A3P2RX7 | |
| SCHEMBL1315430 | 0.83 | ACMSD (0.73) | ACMSDQDPRHTR2CP2RY14SIGMAR1 | |
| SCHEMBL13406397 | 0.81 | ACMSD (0.50) | ACMSDQDPRHTR2CP2RY14SIGMAR1 | |
| Hydrochloric Acid SCHEMBL28221719 | 0.80 | ACMSD (0.49) | ACMSDQDPRHTR2CP2RY14SIGMAR1 | |
| SCHEMBL29138248 | 0.80 | QDPR (0.54) | ACMSDQDPRNOTUMDHODH | |
| SCHEMBL13646124 | 0.79 | P2RY14 (0.44) | ACMSDP2RY14 | |
| SCHEMBL13646123 | 0.79 | P2RY14 (0.44) | ACMSDP2RY14 | |
| SCHEMBL13646126 | 0.79 | P2RY14 (0.44) | ACMSDP2RY14 | |
| SCHEMBL13646125 | 0.79 | P2RY14 (0.44) | ACMSDP2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024057020-A1 | ANTI-VIRAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2024-03-21 | — | — | WO | disclosed |
| US-7598243-B2 | inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598243-B2 | inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2008-04-03 | — | — | US | disclosed |
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | CCR1, CCR5, CCR2 | ACMSD 4046/4885QDPR 171/4885HTR2C 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.